Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,292 papers from all fields of science
Search
Sign In
Create Free Account
monoclonal antibody A27.15
Known as:
A27.15
, ANTI-TRANSFERRIN MOAB 27.15
, MOAB A27.15
A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody A27.15 binds to the Tf receptor, blocking…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Inhibition of Cell Proliferation
Negative Regulation of Receptor Activation
Transferrin Receptor
antigen binding
Broader (1)
Monoclonal Antibodies
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1996
1996
alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies.
M. Caraglia
,
A. Leardi
,
+6 authors
P. Tagliaferri
International Journal of Oncology
1996
Corpus ID: 5707501
We have demonstrated that interferon-alpha 2 recombinant (IFN alpha) inhibits the growth and modulates the expression of the…
Expand
1995
1995
Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro.
J. Kovar
,
P. Naumann
,
B. C. Stewart
,
J. Kemp
Pathobiology (Basel)
1995
Corpus ID: 46868018
We tested non-hematopoietic human tumors for in vitro sensitivity to either a pair of synergistic IgG antitransferrin (Tf…
Expand
1994
1994
Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma.
R. Taetle
,
B. Dos Santos
,
+4 authors
W. Dalton
Journal of the National Cancer Institute
1994
Corpus ID: 24759113
BACKGROUND Although passive serotherapy for cancer with monoclonal antibodies is an attractive concept, it has unfortunately had…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE